introduction
Lapatinib is an orally available inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 and inhibits key downstream signaling pathways mediating cell proliferation and survival. Both mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways are inhibited by lapatinib therapy. In the first phase I dose-escalation study in cancer patients (EGF 10003) lapatinib was well tolerated at doses up to 1800 mg/day [1] . Clinical experience has subsequently demonstrated that most responders express HER-2 at high levels. Several authors [2, 3] have also reported that a minority of patients with HER-2-negative tumors also show benefit. In addition, several studies suggest that lapatinib could be effective in HER-2-negative recurrent breast cancer. Johnston et al. [4] suggested that the addition of lapatinib could potentially benefit HER-2-negative patients who relapse early during tamoxifen therapy, consistent with in vitro models of endocrine resistance that show up-regulation of growth factor (GF) receptors associated with endocrine resistance [5] .
At the time we commenced this study, it was unclear whether treatment-naïve patients with HER-2-negative breast cancer were responsive to lapatinib. Several studies, using the EGFR receptor tyrosine kinase (RTK) inhibitor gefitinib, indicated that some patients with treatment-naïve EGFRexpressing breast cancer may respond to treatment, especially if they expressed the estrogen receptor (ER) [6] . Work in our laboratory had disclosed that gefitinib targeted FOXO3a to mediate cell-cycle arrest [7] and also repressed FOXM1 secondary to the activation of FOXO3a [8] .
We present here the results of a pre-surgical study of 4-6 weeks treatment with the dual EGFR and HER-2 inhibitor lapatinib in women with operable primary breast cancer that did not over express HER-2. The results indicate that lapatinib is not active in this group of breast cancer patients; however, although there was no significant reduction in Ki67 in the total patient population, a significant reduction in Ki67 (≥50%) was observed in a minority of patients, especially those whose breast cancer expressed HER-3.
methods patients
Eligible patients aged ≥18 years with newly diagnosed primary breast cancer ≥10 mm in size according to the ultrasound measurement, not HER-2 over-expressing (as defined by Herceptest; HER-2+++ and/or HER-2 amplified) on core biopsy, and deemed surgically resectable were recruited. Patients could be entered irrespective of menopausal status, with an Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Patients were ineligible if they had received chemotherapy and/or radiotherapy within the previous 2 years. Other anti-cancer medication or oral contraception was prohibited within 2 weeks of the start of the study.
Initially, we sought to recruit solely patients with EGFR-expressing (but HER-2 negative) primary breast cancer, with the objective of ascertaining whether the response was seen equally in EGFR-positive breast cancer, irrespective of ER status. However, after the initiation of the study several groups suggested that the conventional immunohistochemistry underestimated EGFR. Additionally, some reports showed evidence of response to EGFR inhibitors in ER+ breast cancer; and also suggested that the response to EGFR inhibitors occurred irrespective of EGFR status [9] . For these reasons, we altered eligibility to include patients with EGFR-negative breast cancer. study design and conduct LPS was a multicentre, phase II, open-label, window study evaluating the efficacy of 28-42 days of lapatinib before definitive surgery. The primary end point was relative change from baseline to surgery of Ki67 antigen labelling index. The planned analysis compared non-inferiority of log relative change from baseline in EGFR-negative patients (n = 56) against EGFR-positive patients (n = 14). Assuming that the true difference between groups was log(1) with pooled SD 0.1, a non-inferiority margin of log(.9/.98) and one-sided 2.5% significance, the analysis had 81% power. However, following advice from the Independent Data Monitoring Committee (IDMC), the study was terminated early after recruitment of 31 patients (n = 12 EGFR positive and n = 19 EGFR negative) due to slow recruitment. The analysis was thus modified to describe the primary end point for all patients irrespective of either EGFR status in the HER-2-negative population.
The secondary end points were change in the tumor size (clinical and ultrasound assessments), expression of FOXO3a, FOXM1, pAKT and HER-3 (from baseline to post-treatment time points) and toxic effects.
After obtaining informed consent, patients received lapatinib 1500 mg (6 × 250 mg tablets) once daily for a minimum of 28 days and a maximum of 42 days. Patients were followed up weekly whilst on study treatment, again at the time of surgery and 30 days after the final dose of study treatment. Safety and clinical assessments were carried out at each visit, including weight, ECOG status and tumor palpation measurements where possible. Toxicity was assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0 and study drug compliance was recorded using a patient diary card. Haematological and biochemical assessments were carried out at week 2, pre-surgery (week 4-6) and 30-day visits; tumor assessment by ultrasound was carried out at baseline, week 2 and immediately before surgery. Patients had definitive surgery 28-42 days after commencing treatment. Paired formalin-fixed paraffin-embedded (FFPE) tumor samples were obtained at baseline and surgery for the determination of Ki67 and other exploratory biomarkers.
immunohistochemistry EGFR and Ki-67 were determined centrally by the Department of Histopathology at Charing Cross Hospital. FFPE tissue sections (4 µm) were cut and stained according to the local standard operating procedures [10] . The EGFR status was determined using mouse monoclonal EGFR clone 31G7 (1:50), (Zymed, Cambridge Bioscience, Cambridge, UK), on a Bond Autostainer with antigen retrieval in Enzyme 1 (AR9551) (Leica, Milton Keynes, UK) for 10 min. Stained samples were analyzed and EGFR positive samples were defined as those in which >10% of the cells' membranes were stained dark brown. Pre-and post-treatment samples were stained for Ki-67 using the mouse MM-1 monoclonal antibody (1:100) (Leica, Milton Keynes, UK) following recommendations from the International Ki67 in Breast Cancer working group [11] on a Bond autostainer with 30 min antigen retrieval in ER1 (method as per Leica protocol). The initial technique used to score the Ki67-stained sections (Technique A) was as follows: 6-10 photographs were taken using a microscope camera from hot spot areas (areas with the highest Ki-67 staining) at ×200 high power fields. The photographs were printed and used to count the number of positive Ki-67 cells in 2000 tumor cells [12] . These counts were then expressed as percentages (Ki67 score).
An alternative automated technique of Ki67 scoring (Technique B) was undertaken at the Department of Cancer Studies, Leicester University. Here, images were taken of five fields at ×20 and stored and analysed using the freely available image analysis software ImmunoRatio (http://imtmicroscope.uta.fi/immunoratio/) [13] .
Exploratory biomarkers FOX03a, FOXM1, p-AKT and HER-3 were assessed at the Department of Histopathology, Hammersmith Hospital. The sections were stained with the following antibodies: FOX03a ( 
statistical analysis
Continuous variables were summarised by N, mean and Student t distribution 95% confidence interval (CI), median and binomial 95% CI, minimum and maximum. Log normally distributed variables were log transformed before analysis and summaries reported on the original (antilog) scale. Categorical variables were summarised by N and proportion (%). CIs for proportions were calculated by the score method. study management LPS was sponsored by Imperial College London and managed by Imperial Clinical Trials Unit-Section on Cancer. The trial was approved by the Multicentre Research Ethics Committee for Wales (06MRE09/30), the Medicines and Healthcare products Regulatory Agency and by R&D departments at each participating institution. The Trial Management Group (TMG) had overall responsibility for the day-to-day coordination of the trial, and ensured compliance with Good Clinical Practice. A joint IDMC/Trial Steering Committee was responsible for reviewing study data, supervising study progress and advising the TMG (Registered No. ISRCTN71165034).
pet sub study LPS participants with tumors ≥2.0 cm were also offered inclusion into the positron emission tomography (PET) sub-study. Patients had PET-CT scans before and after 2 weeks of therapy (see supplementary data S3, available at Annals of Oncology online, for the scanning protocol).
results
Thirty one patients were recruited from three UK sites between June 2007 and April 2010; the Consort diagram in Figure 1 details the flow of patients from screening to analysis. Two additional sites screened a small number of patients but withdrew from the study without recruiting. Twelve participants had EGFR-positive breast cancers and 19 were EGFR negative. The baseline characteristics of enrolled patients are shown in Table 1 . All 31 patients had HER-2-negative breast cancers defined as HER-2 0, + or ++ (FISH-ve); none were +++. Twenty patients had tumors which were classed as ER positive and 23 of 31 were postmenopausal.
Ki67 results were obtained, using manual scoring Technique A, pre-and postoperatively for 28 patients and overall no change was observed. The range of preoperative Ki67 scores was 0.2-56.5. The geometric mean preoperative score was 5.0 (95% CI 3.0-8.3). The postoperative scores ranged from 0.4 to 32.8 with the geometric mean score of 7.5 (95% CI 5.0-11.2) ( Table 2 ). The geometric mean change in Ki67 was 146% (95% CI 95-225). Despite the lack of response overall, four patients showed a significant reduction (≥50%) in Ki67; in contrast, 14 patients showed a significant rise in Ki67 following treatment. Reduction in Ki67 was not related to ER status; 2 of 18 (11%) ER-positive and 2 of 10 (20%) ER-negative patients showed a significant (≥50%) reduction in Ki67.
Ki67 results were also obtained using automated scoring, pre-and postoperatively for 26 patients (Technique B), see supplementary data S4, available at Annals of Oncology online and Table 3 . Five patients showed a significant reduction (≥50%) in Ki67 and three of five overlapped with Technique A.
Agreement analysis between the Ki67 scores obtained by Techniques A and B was carried out using Bland and Altman [14] , Royston [15] and Altman [16] statistical methods. The agreement between Techniques A and B was poor at low Ki67 scores (95% limits of agreement 0.07-24 at 1% Ki67 score) but improved with increasing Ki67 scores (95% limits of agreement 0.5-3.4 at 55% Ki67 score). The mean bias of the two methods (Technique B/Technique A) was 1.31 (95% CI 0.87-1.98 at 1%, which narrows to 95% CI 1.15-1.50 at 55%) inferring that, on average Technique B scores were 31% higher than those obtained using Technique A, where fewer nuclei were counted (at ×200 magnification). The figure in supplementary data S5, available at Annals of Oncology online, summarises the agreement analysis. Tumor size assessment using a calculation based on the principles of the RECIST criteria was carried out for 25 patients with ultrasound data at the start and end of treatment. Four patients showed partial responses and 17 showed stable disease; only one and three patients, respectively, were accompanied by significant (≥50%) proliferation index reductions in Ki67 using technique A. Of the technique B responders, none were RECIST responders but all five responders showed RECIST stable disease. Of four patients who showed progressive disease on ultrasound during 4 weeks of lapatinib treatment, three showed corresponding increases in Ki67 using technique A (Figure 2 ) and all four using technique B.
relationship of response with other parameters and immunohistochemistry
There was no relationship between menopausal status, HER-2 (+) status or ER status and response, as judged by change in ultrasound or Ki67. There was a previous suggestion in the literature that weakly positive PR immunostaining correlated with response to lapatinib [17] ; eight patients had tumors which were H score either PR+ or PR++, of which two showed a partial response to treatment.
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Baseline immunostaining for FOXO3a, FOXM1, P-AKT and HER-3 showed positive results in 30%, 100%, 22% and 63% of samples, respectively.
The strongest predictor of clinical response or Ki67 response was HER-3 status. Thus, of the 27 patients with initial baseline HER-3 immunohistochemical scoring, the four clinical responders' tumors were all positive, as were three of four Ki67 responders. In aggregate, 6 of 7 patients showing evidence of response on either Ki67 or ultrasound criteria were HER-3 positive, compared with only 11 of 20 non-responders (either Ki67 and/or clinical) whose tumors were HER-3 positive (P = 0.204) (see supplementary data S6, available at Annals of Oncology online, for change in Ki67 for HER-3-positive versus HER-3-negative cases).
Lapatinib treatment did not result in any consistent alteration in the expression of FOXO3a or P-AKT although 3/4 ultrasound responders showed a fall in FOXM1 and/or HER-3 expression, one of whom showed a fall in both. Of the 4 Ki67 responders, two showed a fall in FOXO3a, and one in HER-3. Table 4 shows biomarker changes versus ultrasound changes. Supplementary data S7, available at Annals of Oncology online, shows biomarker changes versus Ki67.
adverse events
The adverse events observed in this study were similar to those previously reported with lapatinib. Two patients showed severe adverse events (CTC grade 3) namely fatigue and raised alanine aminotransferase (ALT). Thirteen patients experienced moderate adverse events (CTC grade 2) comprising fatigue, diarrhoea, rash, anaemia, hyperbilirubinemia, abdominal pain, wheezing, exacerbation of alcoholism, nose bleed, pruritis/ itching, raised ALT and raised aspartate aminotransferase (AST) (see supplementary data S8, available at Annals of Oncology online, for a summary of adverse effects).
PET sub-study
Six patients participated in the PET sub-study using Fluorodeoxyglucose; the geometric mean ultrasound longest axis (mm) at baseline was 28 mm. No patients experienced any side effects from participating in the PET study. All tumors were clearly visualised on PET images with good tumor-background ratios. The results of standardized uptake value (SUV) in tumors are shown in supplementary data S9, available at Annals of Oncology online. The geometric mean SUVmax (95% CI) in all pre-treated tumors was 6.1 (3.0, 12.5) and after 2 weeks of lapatinib it was 5.4 (2.8, 10.5).
The estimated percent change from baseline was not significant: we observed only a 12% reduction in mean SUVmax between pre-treatment and post 2 weeks of treatment (all patients combined). There were three responders based on the PET imaging criteria of a ≥15% change in SUVmax from baseline to week 2 of treatment treatment [18] . The SUVmax in these patients decreased by 21, 35 and 41%; the remaining three patients were classified as PET non-responders.
None of the 3 PET responders were Ki67 responders; however, two PET responders were RECIST responders (defined as partial response or stable disease).
discussion
Several key findings emerge from this report. First, in terms of impact on breast cancer cell proliferation, although there was no significant reduction in Ki67 when all patients are examined together, a reduction in Ki67 in stable or regressing treatment-naïve breast cancer was identified in 4 of 21 (19%) patients using the manual scoring technique and in 5 of 18 (28%) patients using the automated technique; three patients' results concurred. In addition we observed ultrasoundmeasurable regression in four patients, although there was a concomitant reduction in Ki67 in only one of these patients. Thus, in clinical terms, our results demonstrate that lapatinib has an effect on HER-2-negative untreated primary breast cancer during the 4 weeks treatment in only a minority of cases. Of more concern, however, is the marked increase in Ki67 that we observed in some patients; in three of these, this was also accompanied by an increase in tumor size. To our knowledge, stimulation of growth has not been previously observed after lapatinib treatment. This study did not have a placebo arm but our group carried out a study several years ago which showed no change in Ki67 over a 1-month period in 20 postmenopausal patients who had received no therapy (unpublished results). In terms of the role of EGFR in endocrine responsive or resistant breast cancer, our group and others have shown evidence of cross-talk between EGFR and ER [10, 19, 20] . A previous study solely focused on the rare group of breast cancers that co-express ER and EGFR, and showed that the EGFR antagonist gefitinib had some effect in causing tumor regression. However, tumors that co-express ER and EGFR are uncommon; in the study by Polychronis et al [6] , more than 500 cases of ER-positive breast cancers were screened to find around 50 cases. In the current study, 3 of 12 EGFR-positive breast cancers were weakly ER positive.
EGFR signalling in breast cancer remains poorly understood. Inhibition of this pathway has been met with mixed responses; in vitro, most data point to an inhibitory effect in the ERnegative subset of basal tumors, consistent with the expression original article Annals of Oncology of EGFR in the myoepithelial cells in the normal breast. However, clinically, the main effect of inhibition of the EGFR pathway has been seen in ER-positive tumors [6, 21, 22] . This is supported by the finding by Hoadley et al. [23] of the definition of an EGFR-associated signature in a subset of ER-positive, luminal B tumors.
Currently there is consensus that there is little relationship between the EGFR status and benefit from EGFR inhibition, specifically lapatinib therapy in breast cancer [24] . We observed those patients who showed some evidence of benefit, all but one expressed HER-3. It should be noted that the HER-3 findings were derived using multiple comparisons from a small sample size. Nonetheless, the finding of HER-3 being more commonly expressed in Ki67 or ultrasound RECIST responders versus non-responders is of interest and is consistent with the positive results observed in a phase III trial of pertuzumab, a HER-3 dimerisation inhibitor [25] and the suggestion that patients whose tumors co-express HER-3 and HER-2, especially in the phosphorylated form, are more likely to respond to lapatinib [26] .
Recently, some reports have suggested a role for lapatinib in previously-treated ER-positive breast cancer. These results propose that, although lapatinib had no effect on parental cells, it can inhibit proliferation in endocrine-resistant cells, via inhibition of cross-talk, in which ER is activated by membrane ER/EGFR. A randomised study of lapatinib with or without paclitaxel (Taxol) (Bristol-Myers Squibb, NY, USA) showed that the addition of lapatinib increased the PFS in the HER-2-negative subgroup [18] . It is, therefore, possible that the molecular mechanism exemplified in a subset of treated patients is represented in some patients de novo.
Our results indicate that, had the study outlined here been done previously in the case of lapatinib in breast cancer, many thousands of HER-2-negative patients who received lapatinib would have been spared ineffective treatment, suggesting the value of preoperative therapy trials [27] . 
